Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,084 public trials 2,045 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

NCT01587703

Conditions
Blood Protein Disorders, Bronchial Neoplasms, Carcinoma, +31 more
Locations
  • GSK Investigational Site Baltimore, Maryland, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Philadelphia, Pennsylvania, United States
  • GSK Investigational Site Nashville, Tennessee, United States
View all 17 locations
View Trial Details
Completed

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

NCT01569295

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Stanford Cancer Center Palo Alto, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
View all 106 locations
View Trial Details
Completed

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

NCT00918333

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +75 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01478581

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • SITE-13 La Jolla, California, United States
  • SITE-5 Baltimore, Maryland, United States
  • SITE-4 Boston, Massachusetts, United States
  • SITE-8 Ann Arbor, Michigan, United States
View Trial Details

Related conditions